Anti Thymocyte Globulin-Based Treatment for Acquired Bone Marrow Failure in Adults

Idiopathic acquired aplastic anemia can be successfully treated with Anti Thymocyte Globulin (ATG)-based immune suppressive therapy and is therefore considered a T cell-mediated auto immune disease. Based on this finding, several other forms of idiopathic acquired bone marrow failure are treated wit...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jennifer M.-L. Tjon, Saskia M. C. Langemeijer, Constantijn J. M. Halkes
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
Acceso en línea:https://doaj.org/article/dfced9c7352f494ba3359605390d7ce9
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:dfced9c7352f494ba3359605390d7ce9
record_format dspace
spelling oai:doaj.org-article:dfced9c7352f494ba3359605390d7ce92021-11-25T17:08:47ZAnti Thymocyte Globulin-Based Treatment for Acquired Bone Marrow Failure in Adults10.3390/cells101129052073-4409https://doaj.org/article/dfced9c7352f494ba3359605390d7ce92021-10-01T00:00:00Zhttps://www.mdpi.com/2073-4409/10/11/2905https://doaj.org/toc/2073-4409Idiopathic acquired aplastic anemia can be successfully treated with Anti Thymocyte Globulin (ATG)-based immune suppressive therapy and is therefore considered a T cell-mediated auto immune disease. Based on this finding, several other forms of idiopathic acquired bone marrow failure are treated with ATG as well. For this review, we extensively searched the present literature for evidence that ATG can lead to enduring remissions in different forms of acquired multi- or single-lineage bone marrow failure. We conclude that ATG-based therapy can lead to an enduring hematopoietic response and increased overall survival (OS) in patients with acquired aplastic aplasia. In patients with hypocellular myelodysplastic syndrome, ATG can lead to a hematological improvement without changing the OS. ATG seems less effective in acquired single-lineage failure diseases like Pure Red Cell Aplasia, Amegakaryocytic Thrombocytopenia and Pure White Cell Aplasia, suggesting a different pathogenesis in these bone marrow failure states compared to aplastic anemia. T cell depletion is hypothesized to play an important role in the beneficial effect of ATG but, as ATG is a mixture of polyclonal antibodies binding to different antigens, other anti-inflammatory or immunomodulatory effects could play a role as well.Jennifer M.-L. TjonSaskia M. C. LangemeijerConstantijn J. M. HalkesMDPI AGarticleacquired bone marrow failureaplastic anemiapure red cell aplasiaamegakaryocytic thrombocytopeniapure white cell aplasiamyelodysplastic syndromeBiology (General)QH301-705.5ENCells, Vol 10, Iss 2905, p 2905 (2021)
institution DOAJ
collection DOAJ
language EN
topic acquired bone marrow failure
aplastic anemia
pure red cell aplasia
amegakaryocytic thrombocytopenia
pure white cell aplasia
myelodysplastic syndrome
Biology (General)
QH301-705.5
spellingShingle acquired bone marrow failure
aplastic anemia
pure red cell aplasia
amegakaryocytic thrombocytopenia
pure white cell aplasia
myelodysplastic syndrome
Biology (General)
QH301-705.5
Jennifer M.-L. Tjon
Saskia M. C. Langemeijer
Constantijn J. M. Halkes
Anti Thymocyte Globulin-Based Treatment for Acquired Bone Marrow Failure in Adults
description Idiopathic acquired aplastic anemia can be successfully treated with Anti Thymocyte Globulin (ATG)-based immune suppressive therapy and is therefore considered a T cell-mediated auto immune disease. Based on this finding, several other forms of idiopathic acquired bone marrow failure are treated with ATG as well. For this review, we extensively searched the present literature for evidence that ATG can lead to enduring remissions in different forms of acquired multi- or single-lineage bone marrow failure. We conclude that ATG-based therapy can lead to an enduring hematopoietic response and increased overall survival (OS) in patients with acquired aplastic aplasia. In patients with hypocellular myelodysplastic syndrome, ATG can lead to a hematological improvement without changing the OS. ATG seems less effective in acquired single-lineage failure diseases like Pure Red Cell Aplasia, Amegakaryocytic Thrombocytopenia and Pure White Cell Aplasia, suggesting a different pathogenesis in these bone marrow failure states compared to aplastic anemia. T cell depletion is hypothesized to play an important role in the beneficial effect of ATG but, as ATG is a mixture of polyclonal antibodies binding to different antigens, other anti-inflammatory or immunomodulatory effects could play a role as well.
format article
author Jennifer M.-L. Tjon
Saskia M. C. Langemeijer
Constantijn J. M. Halkes
author_facet Jennifer M.-L. Tjon
Saskia M. C. Langemeijer
Constantijn J. M. Halkes
author_sort Jennifer M.-L. Tjon
title Anti Thymocyte Globulin-Based Treatment for Acquired Bone Marrow Failure in Adults
title_short Anti Thymocyte Globulin-Based Treatment for Acquired Bone Marrow Failure in Adults
title_full Anti Thymocyte Globulin-Based Treatment for Acquired Bone Marrow Failure in Adults
title_fullStr Anti Thymocyte Globulin-Based Treatment for Acquired Bone Marrow Failure in Adults
title_full_unstemmed Anti Thymocyte Globulin-Based Treatment for Acquired Bone Marrow Failure in Adults
title_sort anti thymocyte globulin-based treatment for acquired bone marrow failure in adults
publisher MDPI AG
publishDate 2021
url https://doaj.org/article/dfced9c7352f494ba3359605390d7ce9
work_keys_str_mv AT jennifermltjon antithymocyteglobulinbasedtreatmentforacquiredbonemarrowfailureinadults
AT saskiamclangemeijer antithymocyteglobulinbasedtreatmentforacquiredbonemarrowfailureinadults
AT constantijnjmhalkes antithymocyteglobulinbasedtreatmentforacquiredbonemarrowfailureinadults
_version_ 1718412684296192000